General
Preferred name
REGADENOSON
Synonyms
CVT-3146 ()
Lexiscan ()
REGADENOSON ANHYDROUS ()
CVT-3146, Lexiscan ()
Regadenoson hydrate ()
Rapiscan ()
Regadenoson monohydrate ()
P&D ID
PD009316
CAS
313348-27-5
875148-45-1
Tags
available
drug
Approved by
FDA
First approval
2008
Drug indication
retinal artery occlusion
Cardiovascular disease
Radionuclide imaging
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Regadenoson is a selective adenosine A2A receptor agonist, with a substantially longer biological half-life than . (GtoPdb)
ABSORPTION The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. ; T max, injection = 1 to 3 minutes;; Onset of pharmacodynamic response = 1 to 3 minutes; ; E max 12.3 ng/mL ;
HALF-LIFE Initial phase: 2-4 minutes;; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); ; Terminal phase: 2 hours
TOXICITY The most common (incidence ≥ 5%) adverse reactions to regadenoson are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. ; MTD (male, supine position): 20 µg/kg; ; MTD (male, standing position): 10 µg/kg;
PRICE 78
PRICE 120
DESCRIPTION Regadenoson is an A2A adenosine receptor agonist, a coronary vasodilator commonly used in pharmacologic stress testing.
DESCRIPTION Regadenoson (CVT-3146) is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors. (TargetMol Bioactive Compound Library)
Compound Sets
22
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
104
Properties
(calculated by RDKit )
Molecular Weight
390.14
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
5
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
3
cLogP
-2.43
TPSA
186.46
Fraction CSP3
0.4
Chiral centers
4.0
Largest ring
6.0
QED
0.32
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
A2A
Adenosine Receptor
ADORA1, ADORA2A, ADORA2B, ADORA3
Indication
myocardial perfusion imaging (MPI)
MOA
Adenosine Receptor agonist
Pathway
GPCR/G protein
Neuroscience
Source data